Onkológia 5/2024
Practical aspects of daratumumab therapy in the treatment of multiple myeloma
Daratumumab is an anti-CD38 monoclonal antibody approved in combination for newly diagnosed multiple myeloma (MM) patients and as monotherapy and combination therapy for patients with relapsed or refractory MM. The experience with its administration is growing rapidly, which has been reflectes in expert recommendations. The number of various prospective or small retrospective studies published increasing. The article is primarly focused on practical aspect of daratumumab administration.
Keywords: daratumumab, multiple myeloma, toxicity
